A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive BCell Acute Lymphoblastic Leukemia

被引：1
|
作者：
Short, Nicholas J. [1 ]
Kantarjian, Hagop [1 ]
Alvarado, Yesid [1 ]
Burger, Jan A. [1 ]
Jain, Nitin [1 ]
Konopleva, Marina [1 ]
Ravandi, Farhad [1 ]
DiNardo, Courtney D. [1 ]
Masarova, Lucia [1 ]
Sasaki, Koji [1 ]
Thompson, Philip A. [1 ]
Ferrajoli, Alessandra [1 ]
Jacob, Jovitta [1 ]
Milton, Anna [1 ]
Garris, Rebecca [1 ]
Jabbour, Elias J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154124
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2299
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions
    Short, Nicholas J.
    Jabbour, Elias
    Jain, Nitin
    Kantarjian, Hagop
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [42] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN COLOMBIA
    Arciniegas, J.
    Sossa, C.
    Nakandakari, M. L.
    Reyes Sanchez, J. M.
    VALUE IN HEALTH, 2023, 26 (06) : S88 - S88
  • [43] Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database
    Jabbour, Elias
    Stelljes, Matthias
    Advani, Anjali S.
    DeAngelo, Daniel J.
    Goekbuget, Nicola
    Marks, David I.
    Stock, Wendy
    O'Brien, Susan
    Cassaday, Ryan D.
    Wang, Tao
    Neuhof, Alexander
    Vandendries, Erik
    Kantarjian, Hagop
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 2012 - 2015
  • [44] A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
    Brivio, Erica
    Hoogendijk, Raoull
    Chantrain, Christophe
    Rialland, Fanny
    Contet, Audrey
    Elitzur, Sarah
    Dalla-Pozza, Luciano
    Kallay, Krisztian
    Li, Chi Kong
    Kato, Motohiro
    Markova, Inna V.
    Schmiegelow, Kjeld
    Bodmer, Nicole
    Pieters, Rob
    Zwaan, Christian Michel
    BLOOD, 2019, 134
  • [45] Phase II Study of Blinatumomab in Patients with B-Cell Lineage Acute Lymphocytic Leukemia with Positive Minimal/Measurable Residual Disease
    Aboudalle, Iman
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Khouri, Maria
    Takahashi, Koichi
    Ohanian, Maro N.
    Borthakur, Gautam
    Konopleva, Marina Y.
    Daver, Naval G.
    Estrov, Zeev E.
    Alvarado, Yesid
    Jain, Nitin
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Velasquez, Michelle
    Nasnas, Patrice
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2018, 132
  • [46] A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
    Metheny, Leland L.
    Sobecks, Ronald
    Cho, Christina
    Fu, Pingfu
    Margevicius, Seunghee
    Wang, Jiasheng
    Ciarrone, Lisa
    Kopp, Shelby
    Convents, Robin D.
    Majhail, Navneet
    Caimi, Paolo F.
    Otegbeye, Folashade
    Cooper, Brenda W.
    Gallogly, Molly
    Malek, Ehsan
    Tomlinson, Benjamin
    Gerds, Aaron T.
    Hamilton, Betty
    Giralt, Sergio
    Perales, Miguel-Angel
    de Lima, Marcos
    BLOOD ADVANCES, 2024, 8 (06) : 1384 - 1391
  • [47] Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia
    Maurillo, Luca
    Buccisano, Francesco
    Del Principe, Maria Ilaria
    Del Poeta, Giovanni
    Spagnoli, Alessandra
    Panetta, Paola
    Ammatuna, Emanuele
    Neri, Benedetta
    Ottaviani, Licia
    Sarlo, Chiara
    Venditti, Daniela
    Quaresima, Micol
    Cerretti, Raffaella
    Rizzo, Manuela
    de Fabritiis, Paolo
    Lo Coco, Francesco
    Arcese, William
    Amadori, Sergio
    Venditti, Adriano
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) : 4944 - 4951
  • [48] Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report
    Liu, Tong
    Wang, Chang
    Fu, Yu
    Yang, Yan-ping
    Tan, Ye-hui
    MEDICINE, 2024, 103 (29)
  • [49] Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
    Logan, Aaron C.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2022, 35 (04)
  • [50] Measurable Residual Disease in Acute Lymphoblastic Leukemia: Optimization and Innovation in 2021 and Beyond
    Muffly, Lori
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S85 - S87
12345